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RNAi-mediated serotonin transporter suppression
rapidly increases serotonergic neurotransmission and
hippocampal neurogenesis
A Ferre´s-Coy1,2, F Pilar-Cuellar2,3, R Vidal2,3, V Paz1,2, M Masana1,2,7, R Corte´s1,4, MC Carmona5, L Campa1,2, A´ Pazos2,3,
A Montefeltro5, EM Valdiza´n2,3, F Artigas1,2 and A Bortolozzi1,2,6
Current antidepressants, which inhibit the serotonin transporter (SERT), display limited efficacy and slow onset of action. Here,
we show that partial reduction of SERT expression by small interference RNA (SERT-siRNA) decreased immobility in the tail
suspension test, displaying an antidepressant potential. Moreover, short-term SERT-siRNA treatment modified mouse brain
variables considered to be key markers of antidepressant action: reduced expression and function of 5-HT1A-autoreceptors,
elevated extracellular serotonin in forebrain and increased neurogenesis and expression of plasticity-related genes (BDNF,
VEGF, Arc) in hippocampus. Remarkably, these effects occurred much earlier and were of greater magnitude than those evoked
by long-term fluoxetine treatment. These findings highlight the critical role of SERT in serotonergic function and show that the
reduction of SERT expression regulates serotonergic neurotransmission more potently than pharmacological blockade of SERT.
The use of siRNA-targeting genes in serotonin neurons (SERT, 5-HT1A-autoreceptor) may be a novel therapeutic strategy to
develop fast-acting antidepressants.
Translational Psychiatry (2013) 3, e211; doi:10.1038/tp.2012.135; published online 15 January 2013
Introduction
Despite the high prevalence of depression and its consider-
able socioeconomic impact, its pathophysiological mechan-
isms remain poorly understood.1–3 Serotonin (5-HT)
participates in the etiology and treatment of major depression,
being the selective serotonin reuptake inhibitors (SSRIs), the
most common antidepressant therapy. However, SSRIs need
to be administered for long time periods before clinical
improvement emerges, and fully remit depressive symptoms
in only one third of patients.4–6
The serotonin transporter (SERT) is a key regulator of
serotonergic neurotransmission, as it controls the active
fraction of 5-HT. In the brain, SERT is localized to raphe 5-
HT neurons at somatodendritic and terminal levels.7–9 SERT
blockade by SSRIs (showing nM affinity for SERT)10 initiates
the chain of events leading eventually to clinical improvement.
Long-term SSRI treatment promotes an internalization of
SERT from the cell surface in 5-HT neurons without affecting
SERT mRNA expression.11–15 In addition to loss of 5-HT1A-
autoreceptor function,16–18 SERT down-regulation may
enhance forebrain 5-HT neurotransmission contributing to
the therapeutic action of SSRIs.19,20
Polymorphic variations in SERT transcriptional region—
leading to reduced SERT expression and function—are
involved in multiple neuropsychiatric disorders, including
major depression,21–25 and in the clinical response to
SSRI.26,27 SERT-knockout mice were generated to gain
further insight into the role of SERT in the pathophysiology
and treatment of depression.28,29 However, these mice
showed depression-related behaviors attributable to the
developmental changes that result from SERT early-life
absence and the perturbed 5-HT function.30–32 Thus, while
SERT-knockout mice represent a useful model to investigate
disorders involving genetic alterations in SERT during early
life, they are less appropriate to study downstream changes of
5-HT transmission secondary to SERT blockade in adulthood.
RNA interference (RNAi) has a critical role in regulating
gene expression.33,34 It also provides new alternatives to
pharmacological treatments to modulate brain neurotrans-
mission through the use of exogenous small interference RNA
(siRNA). Recent studies have shown the feasibility to silence
the expression of critical genes in 5-HT neurons, such as
SERT and the 5-HT1A-autoreceptor.
18,35 Given the above
limitations of SERT-knockout mice, here we evaluated the
specificity and selectivity of partial SERT suppression in adult
mice, following short-term SERT-siRNA treatment. We
examined downstream changes on brain variables linked to
antidepressant efficacy and compared SERT-siRNA effects
with those of a standard SSRI (fluoxetine) treatment. The
results indicate that the post-transcriptional regulation of
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SERT may constitute a target for fast-acting antidepressants,
thus bringing RNAi closer to the clinic as a potential therapy for
major depression.
Materials and methods
Animals. Male C57BL/6J mice (10–14 weeks; Charles
River, Lyon, France) were housed under controlled conditions
(22±1 1C; 12 h light/dark cycle) with food and water available
ad libitum. Animal procedures were conducted in accordance
with standard ethical guidelines (EU regulations L35/118/12/
1986) and approved by the local ethical committee.
Drug/siRNA treatments. SERT-targeting siRNA (nt:1230–
1250, GenBank accession NM_010484) and an unrelated
siRNA with no homology to mouse genome (nonsense siRNA,
ns-siRNA) were used (Life Technology, Madrid, Spain). The
siRNA sequences are shown in Supplementary Table S1.
Mice were anesthetized (pentobarbital, 40 mg kg 1, intra-
peritoneally, i.p.) and silica capillary microcannula (110 mm-
outer diameter (OD), 40 mm-inner diameter (ID); Polymicro
Technologies, Madrid, Spain) were stereotaxically implanted
into the dorsal raphe nucleus (DR; coordinates in mm: anter-
oposterior,  4.5; mediolateral,  1.0; dorsoventral,  4.4;
with a lateral angle of 201).36 Local siRNA microinfusion was
performed with a perfusion pump at 0.5ml min 1 24 h after
surgery in awake mice as described previously.18 siRNAs were
prepared in artificial cerebrospinal fluid (125 mM NaCl, 2.5 mM
KCl, 1.26 mM CaCl2 and 1.18 mM MgCl2 with 5% glucose) and
infused intra-DR once daily at the dose of 10mgml 1 (0.7 nmol
per dose). Mice received two dose in 2 consecutive days, or
four dose in 5 days (days 1, 2, 4 and 5), and were killed on 3rd or
6th day, respectively. An additional group of mice received
seven dose in 9 days (days 1, 2, 3, 5, 6, 8 and 9) and was killed
on 10th-day. In the last group, only in situ hybridization and
autoradiography studies were performed (see below). Control
mice received artificial cerebrospinal fluid.
Fluoxetine (Tocris, Madrid, Spain) was prepared in saline
and was administered once daily at 20 mg kg 1 dose, i.p. for
4, 7 or 15 days. Mice were killed on 5th, 8th or 16th day,
respectively. Control mice received saline.
In situ hybridization and autoradiographic studies
Tissue preparation. Mice were killed by pentobarbital over-
dose and brains rapidly removed, frozen on dry ice and
stored at  80 1C. Tissue sections (14 mm thick-coronal)
were cut using a microtome-cryostat (HM500-OM, Microm,
Walldorf, Germany), thaw-mounted onto 3-aminopropyl-
triethoxysilane (Sigma-Aldrich, Madrid, Spain)-coated slides
and kept at  20 1C until use.
In situ hybridization. Antisense oligoprobes [33P]-labeling
and in situ hybridization procedures were carried out as
described previously.18 Mouse SERT, 5-HT1AR, tryptophan
hydroxylase 2, Ki-67, brain-derived neurotrophic factor
(BDNF), vascular endothelial growth factor (VEGF), activ-
ity-regulated cytoskeletal protein (Arc), and cAMP response
element binding protein (CREB) probes were synthesized by
IBA-GmbH (Go¨ttingen, Germany). Details can be found in
the Supplementary Information.
Receptor autoradiography. The autoradiographic binding
assays for 5-HT1AR, SERT and norepinephrine transporter
were performed using the following radioligands: (a)
[3H]-8-OH-DPAT (233 Ci mmol 1), (b) [3H]-citalopram
(70 Ci mmol 1) and (c) [3H]-nisoxetine (85 Ci mmol 1),
respectively (Perkin-Elmer, Madrid, Spain).18,37 Experimen-
tal conditions are summarized in Supplementary Table S2.
5-HT1AR-stimulated [
35S]GTPcS autoradiography. Label-
ing of DR sections with [35S]GTPgS was performed as
described previously.38 Autoradiograms were analyzed and
the relative optical densities (ROD) were obtained using a
computer-assisted image analyzer (AIS, Imaging Research,
St Catherines, Ontario, Canada). Details are shown in
Supplementary information.
5-Bromo-20-deoxyuridine administration. 5-Bromo-20-
deoxyuridine was purchased from Sigma-Aldrich (Madrid,
Spain) and dissolved in saline solution. Mice were injected
with 4 75 mg kg 1 5-Bromo-20-deoxyuridine every 2 h, i.p.,
the last day of antidepressant treatments. Mice were killed
24 h later.
Immunohistochemistry. Animals were deeply anesthe-
tized with pentobarbital and transcardially perfused with 4%
paraformaldehyde in sodium-phosphate buffer (pH¼ 7.4).
Brains were collected, post-fixed 24 h at 4 1C in the same
solution, and then placed in gradient sucrose or phosphate-
buffered saline 10–30% for 2 days at 4 1C. After
Figure 1 Serotonin transporter-small interference RNA (SERT-siRNA) treatment, but not fluoxetine (FLX), downregulates SERT mRNA and protein levels. Mice were
infused with two-, four- or seven-dose SERT- or nonsense siRNA (ns-siRNA) (10mg–0.7 nmol per day) or vehicle into the dorsal raphe nucleus (DR). Other groups of mice
were treated with 4, 7 or 15-day FLX (20 mg kg 1 per day, intraperitoneally) or saline. (a) Representative coronal brain sections showing reduced SERT expression in the DR
of mice treated with SERT-siRNA (four dose), but not with FLX, as assessed by in situ hybridization. Scale bar¼ 500mm. (b) Bar graphs showing no differences in SERT
mRNA level in DR and median raphe nucleus (MnR) of FLX-treated mice. However, SERT-siRNA at different doses significantly reduced SERT mRNA level exclusively in DR
(n¼ 5–10 mice per group). Two-way analysis of variance revealed a significant effect of group (F2,33¼ 59.32, Po0.001). (c) Representative images of SERT-
immunoreactive (SERT-ir) axons in the hippocampal CA1 region. Short-term SERT-siRNA treatment (four dose) significantly decreased the target SERT protein density as
compared with vehicle and ns-siRNA-treated mice. In contrast, FLX treatment did not alter SERT-ir axon density. Box insets represent regions of high-magnification
photomicrographs. Scale bars: lower magnification¼ 100mm and high magnification¼ 20mm. (d) SERT-ir fiber density in different hippocampal subfields including CA1,
CA2, CA3 and dentate gyrus (DG) was measured and expressed as the percentage of the density in the respective vehicle-treated mice (n¼ 4–6 mice per group). Two-way
ANOVA showed an effect of group (F2,11¼ 11.16, Po0.01). (e) Local citalopram (SSRI) infusion by reverse dialysis induced a concentration-dependent increase of
extracellular 5-HT in caudate putamen (CPu) of vehicle-treated mice (n¼ 7). However, this effect was lesser marked in SERT-siRNA-treated mice (n¼ 9). Two-way ANOVA
showed an effect of group (F1,14¼ 17.17, Po0.0001), concentration (F3,42¼ 27.06, Po0.0001) and group-by-concentration interaction (F3,42¼ 7.72, Po0.0001).
*Po0.05, **Po0.01, ***Po0.001 compared with vehicle and ns-siRNA-treated mice. Values are mean±s.e.m.
SERT-siRNA hastens antidepressant effects
A Ferre´s-Coy et al
3
Translational Psychiatry
cryopreservation, 30-mm-thick free-floating coronal brain
sections were processed for immunohistochemical visualiza-
tion of SERT, BdrU, Ki-67, NeuroD, NeuN, Doublecortin
(DCX), GFAP and IBA-1 by using the biotin-labeled antibody
procedure. Details are shown in Supplementary Information.
Intracerebral microdialysis. Extracellular serotonin con-
centration was measured by in vivo microdialysis.18,39 Details
are shown in the Supplementary Information.
Tail suspension test. Mice were moved from the housing
room to the testing area in their home cages and allowed to
adapt to the new environment for at least 1 h before testing.
Mice were suspended 30 cm above the bench by adhesive
tape placed B1 cm from the tip of the tail. The total duration
of immobility during a 6 min test was measured.
Statistical analysis. Data are expressed as means±s.e.m.
Data were analyzed with Student’s t-test, one- two- or three-
way analysis of variance as appropriate followed by post-hoc
test (Newman-Keuls). The level of significance was set at
Po0.05.
Results
In vivo characterization of SERT knockdown in mice.
We first examined the feasibility to acutely suppress in vivo
SERT expression in raphe 5-HT neurons using a
SERT-siRNA. Mice were locally infused with: (a) vehicle,
(b) ns-siRNA or (c) SERT-siRNA (10mg per dose) into
DR for 2 consecutive days using a protocol similar to that
inducing 5-HT1A-autoreceptor knockdown.
18,40 Histological
analysis revealed a significant decrease of SERT expression
in DR—but not in median raphe nucleus (MnR)—of
SERT-siRNA-treated mice (SERT mRNA and binding
levels were 63±4% and 70±8%, respectively versus vehicle
and ns-siRNA-treated mice). Neither treatment altered
the raphe expression of norepinephrine transporter,
5-HT1AR and tryptophan hydroxylase 2 (Supplementary
Figure S1a–d).
Next, we evaluated the potential neurotoxic effects of
SERT-siRNA infusion by immunohistochemical staining for
NeuN, GFAP and IBA-1 (neuronal, astrocyte and microglial
markers, respectively). Compared with control groups
(ns-siRNA and vehicle), SERT-siRNA-treated mice showed
no loss of NeuN-positive neurons in DR. In addition, a mild
increase in DR GFAP was noted in all experimental groups,
likely due to the reactive astrogliosis secondary to the
microcannula implant. Likewise, IBA-1-stained sections in
each group showed no increase in activated microglia, except
for within the injection tracts (Supplementary Figure S2a–c).
The functional impact of siRNA-induced acute SERT
reduction was assessed by in vivo microdialysis in caudate
putamen (CPu), a forebrain area exclusively innervated by DR
5-HT fibers.41 Local 50 mM veratridine application produced a
similar increase of extracellular 5-HT in CPu of all groups,
indicating that SERT knockdown did not alter the impulse-
dependent 5-HT release. However, 1 mM citalopram (SSRI)
infusion by reverse dialysis increased 5-HT concentration in
CPu of vehicle (170±27% of baseline) and ns-siRNA-treated
mice (180±15%), but not of SERT-siRNA-treated mice
(83±8%), reflecting a decreased SERT expression/function
in the latter group (Supplementary Figure S3a). In addition,
fluoxetine administration (SSRI; 20 mg kg 1, i.p.) enhanced
extracellular 5-HT in CPu of vehicle-treated mice
(8.0±1.0 fmol per fraction), reaching the basal values in
SERT-siRNA-treated mice (10.0±0.6 fmol per fraction)
(Supplementary Figure S3b). Next, the efficacy of SERT-
siRNA infusion was tested in the tail suspension test, a highly
reliable predictor of clinical antidepressant potential.42,43 Mice
treated with SERT-siRNA showed a significant reduction of
the immobility time compared with control groups
(Supplementary Figure S3c).
Different regulation of SERT mRNA and protein levels
after SERT-siRNA or fluoxetine treatment. Following
verification the effectiveness of SERT suppression by acute
SERT-siRNA, we evaluated the effect on SERT regulation
after short-term SERT-siRNA administration and its time
course. Mice were infused intra-DR with four- or seven-dose
Figure 2 (a–f) Short-term serotonin transporter-small interference RNA (SERT-siRNA) treatment, but not fluoxetine (FLX), reduces 5-HT1A-autoreceptor expression and
function. Mice were infused with four or seven dose SERT- or nonsense siRNA (ns-siRNA; 10mg per day) or vehicle into dorsal raphe nucleus (DR). Other groups of mice were treated with
4, 7 or 15-day FLX (20 mg kg 1 per day, intraperitoneally (i.p.) or saline. (a) Representative coronal midbrain sections showing [3H]-8-OH-DPAT binding to 5-HT1AR in DR. The arrow
indicates the decreased DR 5-HT1AR density in SERT-siRNA-treated mice (four dose). Scale bar¼ 2 mm. (b) Bar graphs showing no differences in DR 5-HT1AR mRNA levels of vehicle-
and FLX-treated mice. However, SERT-siRNA significantly reduced 5-HT1AR mRNA level in DR compared with vehicle and ns-siRNA groups (n¼ 3–5 mice per group). Two-way analysis
of variance (ANOVA) revealed an effect of group (F2,15¼ 22.59, Po0.001). (c) Quantitative [3H]-8-OH-DPAT binding showed a decreased DR 5-HT1AR density after SERT-siRNA
treatment, but not with FLX (n¼ 4–7). Two-way ANOVA showed a significant effect of group (F2,15¼ 20.69, Po0.001). (d) Autoradiograms of coronal midbrain sections of mice showing
5-HT1AR 8-OH-DPAT agonist-stimulated [
35S]GTPgS binding. Scale bar¼ 500mm. (e) FLX induced a decreased DR 8-OH-DPAT-stimulated [35S]GTPgS binding from days 7 to 15 of
treatment (n¼ 5–8). Two-way ANOVA showed an effect of group (F3,25¼ 11.40, Po0.001). However, SERT-siRNA produced a fast 5-HT1A-autoreceptor desensitization detected after
four dose treatment (n¼ 4–8). Two-way ANOVA revealed an effect of group (F2,31¼ 10.47,Po0.001). (f) The 5-HT1AR agonist 8-OH-DPAT (0.5 mg kg 1, i.p.) decreased extracellular 5-
HT concentration in ventral hippocampus (HPC) of saline- and FLX-treated mice (4-day), but not after 15-day FLX treatment (n¼ 5–9). Two-way ANOVA showed an effect of group
(F2,18¼ 41.32, Po0.0001), time (F10,180¼ 13.96, Po0.001) and interaction (F20,180¼ 4.41, Po0.001). Similarly, 8-OH-DPAT had no effect on ventral HPC 5-HT release in SERT-
siRNA-treated mice (four-dose), unlike to control groups (n¼ 4). Two-way ANOVA showed an effect of group (F2,8¼ 23.13, Po0.0001), time (F10,80¼ 6.38, Po0.001) and interaction
(F20,80¼ 4.41, Po0.001). (g–h) Time course of the increase in extracellular 5-HT levels in forebrain. Mice received an intra-DR infusion of two or four dose siRNA or vehicle. Microdialysis
experiments were performed on the 3rd or 6th day, respectively. In addition, groups of mice were treated with FLX (20 mg kg 1 per day, i.p.) or saline and microdialysis experiments were
performed 24 h after the last administration on 2nd, 3rd, 4th, 5th, 7th, 8th and 16th day. (g) FLX treatment significantly increased extracellular 5-HT levels in caudate putamen (CPu) from six
dose onwards, compared with saline-treated mice (F13,80¼ 7.43, Po0.0001; n¼ 7–10 mice per group). In contrast, SERT-siRNA-treated mice displayed a larger and faster increase in
CPu 5-HT levels, which was significantly different from control already after two-dose treatment (F5,60¼ 32.52, Po0.0001; n¼ 7–12 mice per group). (h) Long-term FLX treatment (15
dose) also increased 5-HT levels in ventral HPC compared with saline-treated mice (F3,20¼ 39.93, Po0.0001; n¼ 4–9). SERT-siRNA-treated mice (four dose) also showed a rapid and
significant increase of HPC 5-HT levels relative to vehicle and ns-siRNA-treated mice (F2,18¼ 14.51, Po0.001; n¼ 4–9 mice). ^ ^Po0.01, ^ ^ ^Po0.001 versus saline-treated mice;
*Po0.05, **Po0.01, ***Po0.001 versus vehicle and ns-siRNA-treated mice. Values are mean±s.e.m.
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SERT- or ns-siRNA (10 mg per dose) or vehicle during 5 and
9 days, respectively. The effects on SERT expression were
compared with those in mice treated with fluoxetine
(20 mg kg 1 per day, i.p.) or saline for 4, 7 or 15 days.
Short-term SERT-siRNA infusion evoked a regionally
selective (only in DR) and dose-dependent reduction of
SERT mRNA expression. This reduction was not observed
in control mice (vehicle and ns-siRNA) nor in any of the
fluoxetine-treated groups (Figures 1a and b). As SERT is
localized in the somatodendritic and terminal regions of raphe
5-HT neurons,7 [3H]-citalopram autoradiography was per-
formed to quantify SERT-binding sites in different brain
regions along the rostro-caudal axis. Repeated SERT-siRNA
infusion, but not ns-siRNA, significantly reduced SERT
binding by B30%–40% in most brain regions analyzed.
Differences in the extent of the reduction likely reflect the DR/
MnR origin of serotonergic fibers in each region
(Supplementary Figure S4).
In contrast, a specific [3H]-citalopram signal was undetect-
able in fluoxetine-treated mice (4, 7 or 15 days), likely owing to
the long half-life of fluoxetine. Additional SERT autoradio-
graphy binding was performed in fluoxetine-treated mice (4 or
7-day) and subjected to a 48–96 h washout before killed to
reduce fluoxetine serum concentrations.13,44 Even in these
conditions, a specific [3H]-citalopram binding was not
observed (data not shown).
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Next, we examined the density of SERT-containing fibers in
several brain areas, including different hippocampus (HPC)
subfields (Figure 1c and Supplementary Figure S5) where
neurogenesis was evaluated (see below). Short-term SERT-
siRNA treatment (four dose) caused a rapid and significant
decrease of SERT-immunolabeling in different HPC areas
relative to vehicle- and ns-siRNA-treated mice. However,
SERT-immunolabeling was equal in fluoxetine-treated mice
and their respective controls (Figures 1c and d). The presence
of an immunohistochemical SERT signal in fluoxetine-treated
mice indicates that the lack of specific [3H]-citalopram binding
was due to competence with fluoxetine present in the tissue
sections. Likewise, these data highlight the different mechan-
ism of regulation of SERT expression. Thus, whereas SERT-
siRNA-induced post-transcriptional changes lead to SERT
mRNA knockdown and a subsequent fall in protein density,
we did not find an effect of fluoxetine on SERT expression, as
previously reported.45,46
In agreement with this partial SERT suppression, a
decreased SERT function was observed in SERT-siRNA-
treated mice (four dose). Hence, local application of citalo-
pram (1–10–50 mM) produced much smaller increases of
extracellular 5-HT in the CPu relative to vehicle controls
(Figure 1e).
Short-term SERT-siRNA treatment, but not fluoxetine,
reduces 5-HT1A-autoreceptor expression and function.
The functional down-regulation of presynaptic 5-HT1AR (5-
HT1A-autoreceptors) is required for the clinical antidepres-
sant action.16,38,47,48 Indeed, the degree of 5-HT1AR-
mediated inhibition of 5-HT by SSRIs has been used as a
reliable index of their sensitivity.49,50 As expected, 5-HT1A-
autoreceptor expression was unchanged in any of the
fluoxetine-treated groups (Figures 2a–c). However, 7 and
15-day fluoxetine administration (but not 4-day) attenuated 8-
OH-DPAT-stimulated [35S]GTPgS binding in the DR, indicat-
ing a decrease in G-protein coupling efficiency of 5-HT1AR
(Figures 2d and e). In contrast, a short-term SERT-siRNA
treatment significantly reduced 5-HT1A-autoreceptor expres-
sion and produced a concomitant loss of function as
assessed by [35S]GTPgS binding (Figures 2a–e).
Likewise, the 5-HT1AR agonist 8-OH-DPAT (0.5 mg kg
 1,
i.p.) significantly decreased 5-HT release in the HPC of
vehicle (62±4% of baseline) and mice treated with fluoxetine
for 4 days (61±4%), but not in those treated for 15 days
(99±2%) (Figure 2f). Interestingly, 8-OH-DPAT did not
reduce hippocampal 5-HT release in four-dose SERT-
siRNA-treated mice (103±5% of baseline), unlike in control
groups (vehicle: 70±3% and ns-siRNA: 65±2%) (Figure 2f).
This indicates a very fast attenuation of 5-HT1A-autoreceptor
sensitivity in SERT-siRNA-treated mice, as observed after
long-term pharmacological blockade of SERT.47,51
Time course of forebrain extracellular 5-HT concentra-
tion after SERT-siRNA or fluoxetine treatment. We next
assessed the kinetics of extracellular 5-HT levels after
SERT-siRNA or fluoxetine treatment using in vivo micro-
dialysis. Basal extracellular 5-HT levels in CPu and HPC of
control mice were: 3.4±0.3 fmol per fraction (n¼ 49) and
1.7±0.1 fmol (n¼ 9) per fraction, respectively. Further,
baseline 5-HT levels of mice implanted with a silica
microcannula into DR were: 3.9±0.4 fmol per fraction
(CPu, n¼ 25) and 2.4±0.5 fmol per fraction (HPC, n¼ 10).
No significant differences were detected between groups.
Repeated fluoxetine administration induced a progressive
and significant increase of 5-HT levels in CPu from days 6 to
15 of treatment compared to their respective saline-treated
controls (Figure 2g). SERT-siRNA-treated mice displayed a
larger and faster increase in CPu 5-HT levels, which was not
seen in control groups. Extracellular 5-HT in CPu of mice
treated with four doses of SERT-siRNA was greater than after
15-day fluoxetine administration (Figure 2g). Similar results
were seen in HPC, where SERT-siRNA (four doses)
increased extracellular 5-HT to the same extent than a 15-
day treatment with fluoxetine (Figure 2h). Regional differ-
ences are likely owing to the greater contribution of DR axons
in CPu versus HPC.52
SERT-siRNA treatment induces faster adult neurogen-
esis than fluoxetine. We then addressed whether the
above temporal differences between SERT-siRNA and
fluoxetine translated into the proliferative activity in dentate
gyrus (DG), a key feature of antidepressant treatments. To
this end, mice were injected with the proliferation marker
BdrU on the last day of the antidepressant treatments.
Twenty-four hours later, BdrU incorporation was quantified in
DG. Remarkably, SERT-siRNA (four dose) significantly
enhanced the number of BdrU-labeled cells to 144±8% of
vehicle-treated mice. No effect was observed in ns-siRNA-
treated mice (Figures 3a and b). Detailed morphological
analysis revealed that these cells were grouped in clusters,
suggesting an acute induction of mitotic activity. Such
clusters of BdrU-positive cells were detectable after 15-day
(but not 4-day) fluoxetine treatment (BdrU-positive cells:
Figure 3 Serotonin transporter (SERT) silencing accelerates neural proliferation in the adult hippocampus compared with fluoxetine (FLX). Mice were infused with four
dose SERT- or nonsense siRNA (ns-siRNA; 10 mg per day) or vehicle into dorsal raphe nucleus (DR). Other groups of mice were treated with 4 or 15-day FLX (20 mg kg 1 per
day, intraperitoneally) or saline. (a) Representative images showing an increased number of 5-Bromo-20-deoxyuridine (BdrU)-positive cells in the dentate gyrus (DG) of FLX-
treated mice (15-day) or serotonin transporter-small interference RNA (SERT-siRNA)-treated mice (four dose) compared with their respective control mice. Box insets frame
regions of high-magnification photomicrographs shown below. Scale bars: lower magnification¼ 100mm and high magnification¼ 20mm. (b) Cell proliferation was assessed
by the number of BdrU-positive cells (n¼ 5–8 mice) and Ki-67-positive cells (n¼ 5–9 mice) in the granule cell layer. Quantitative analysis indicated a significant increase in
both BdrU- and Ki-67-positive cell number for longer treatment with FLX (BdrU: F2,20¼ 53.16; Ki-67: F2,17¼ 20.72) or SERT-siRNA (BdrU: F2,13¼ 14.10; Ki-67: F2,18¼ 6.26).
(c) Representative coronal brain sections showing Ki-67 expression in DG assessed by in situ hybridization. Scale bar¼ 100mm. (d) Bar graph showing increased Ki-67
mRNA levels in DG following FLX (15-day) and SERT-siRNA (four dose) treatment as compared with respective control groups (n¼ 3–4 mice). One-way analysis of variance
revealed a significant effect of group (F4,11¼ 9.73, Po0.01). ^Po0.05, ^ ^ ^Po0.001 versus saline-treated mice; *Po0.05, **Po0.01 versus vehicle and ns-siRNA-treated
mice. Values are mean±s.e.m.
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91±5 and 229±16% following 4- and 15-day fluoxetine
relative to saline group) (Figures 3a and b). Moreover, we
confirmed the effects on neural progenitor cell proliferation,
assessing the intrinsic Ki-67 expression in DG.53,54 Both Ki-
67 mRNA level and Ki-67-positive cells were significantly
increased in the DG of SERT-siRNA- and fluoxetine-treated
mice following 4 and 15-day of administration, respectively,
compared with their control groups (Figures 3b–d).
In addition, an increase in NeuroD-positive cells was seen
in the subgranular cell layer of DG after four-dose SERT-
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siRNA treatment (129±5% of vehicle), whereas fluoxetine
administration (15-day) led to a slight, but non-significant
increase in the number of immature neurons (NeuroD-positive
cells: 115±10% of vehicle) (Figures 4a and b). To assess
whether SERT-siRNA regulates neuronal cell migration,
DCX-immunostaining was performed. SERT-siRNA treat-
ment (four-dose) significantly enhanced the number of DCX-
positive cells in the DG (137±9% of vehicle) compared with
control groups. Similar data were obtained after 15-day
fluoxetine administration (DCX-positive cells: 121±4% of
vehicle) (Figures 4c and d).
Short-term SERT-siRNA treatment, but not fluoxetine,
enhances hippocampal plasticity-associated gene
expression. As the final step of the present study, we
assessed whether SERT-siRNA (four dose) was able to
increase the hippocampal expression of trophic factors such
as BDNF and VEGF, which are known to be enhanced only
after prolonged (2–3 weeks) antidepressant treatments.55–57
We also examined the effects on the expression of the
immediate early gene Arc and the transcription factor CREB,
which are also regulated by chronic antidepressant treat-
ments and contribute to the antidepressant efficacy.58,59 We
found that SERT-siRNA infusion (four dose) robustly and
significantly increase BDNF mRNA levels in the different
hippocampal areas (CA1: 134±9%, CA3: 144±9% and DG:
122±2% of vehicle) (Figure 5a). A 15-day fluoxetine
treatment (but not 4-day) increased BDNF mRNA expression
only in DG (151±25%). Likewise, SERT-siRNA (four dose)
significantly enhanced VEGF expression in all HPC subfields
(B125%), as produced by 15-day fluoxetine treatment
(Figure 5b).
Furthermore, SERT-siRNA (four dose) significantly upre-
gulated the Arc mRNA expression in CA1 and DG (B135%),
an effect that was observed in DG only after 15-day fluoxetine
treatment (190±27%) (Figure 5c). In contrast to these
changes, neither SERT-siRNA nor fluoxetine altered hippo-
campal CREB mRNA expression (Figure 5d).
Discussion
The present study shows that partial RNAi-based reduction of
SERT expression in mouse DR has dramatic effects on
serotonergic neurotransmission. Short-term SERT-siRNA
treatment evoked a number of changes in behavioral,
neurochemical and cellular variables predictive of therapeutic
antidepressant activity, such as (i) reduced immobility time in
the tail suspension test, (ii) increased extracellular 5-HT
concentration, (iii) downregulated 5-HT1A-autoreceptor
expression/function, (iv) enhanced hippocampal
neurogenesis and (v) increased hippocampal expression of
plasticity-associated genes. Remarkably, these changes
occurred much earlier and were in general of greater
magnitude than those evoked by long-term SSRI-fluoxetine
administration. Together with earlier reports,18,35,40 this study
illustrates the therapeutic potential of siRNA-based strategies
in the treatment of major depression. In particular, our data
highlight the relevance of post-transcriptional SERT regula-
tion as a new therapeutic approach to develop fast-acting
antidepressants.
We previously showed that unmodified siRNA infusion into
the mouse DR and also, intracerebroventricular or intranasal
administration of a conjugated siRNA can efficiently and
selectively reduce 5-HT1A-autoreceptor expression in 5-HT
neurons, thus evoking antidepressant responses.18,40 Here,
we suppressed SERT expression, another key mechanism
controlling brain serotonergic transmission. RNAi-induced
reduction of SERT level triggers remarkable effects on
serotonergic function, faster and more efficient than those
produced by the pharmacological SERT blockade. Thus,
forebrain 5-HT concentration was increased three- and four-
fold by two and four doses of SERT-siRNA, respectively, an
effect similar to that found after 2-week fluoxetine treatment at
a daily dose showingB90% SERT occupancy.60 The robust
effect on extracellular 5-HT, compared with the relatively
modest change in SERT expression (consistent with its half-
life,B3 days),61 suggests that functional SERT derives from
newly synthesized pools.
As expected from the increased serotonergic function,
resulting from the decreased SERT level, mice treated with
very small SERT-siRNA (1.4 nmol) showed a marked reduc-
tion of immobility in the tail suspension test, a behavioral
response evoked by antidepressant drugs.18,42 An earlier
study also found antidepressant-like effects in the forced swim
test but after a prolonged intracerebroventricular SERT-
siRNA infusion during 2-week at a higher dose (31 nmol per
day).35 Overall, this indicates that SERT knockdown in
adulthood significantly improves the resilience to stress, thus
contributing to the antidepressant action.
The fast increase of extracellular 5-HT observed in SERT
knockdown mice likely accounts for the rapid desensitization
of 5-HT1A-autoreceptors, a key characteristic of antidepres-
sant drugs. Indeed, 5-HT1A-autoreceptor stimulation by the
excess 5-HT produced by SSRIs reduces raphe 5-HT
neuronal firing and, consequently, 5-HT neurotransmission
in forebrain.16 Only after successful 5-HT1A-autoreceptor
desensitization, 5-HT neuron activity and terminal 5-HT
release are recovered.17,47 In agreement with these previous
studies, fluoxetine desensitized 5-HT1A-autoreceptors after
2-week treatment. Interestingly, short-term SERT-siRNA
Figure 4 Serotonin transporter (SERT) silencing rapidly increases the number of NeuroD- and DCX-positive cells in hippocampus. Mice were infused with four dose
SERT- or nonsense siRNA (ns-siRNA; 10 mg per day) or vehicle into dorsal raphe nucleus (DR). Other groups of mice were treated with 4 or 15-day fluoxetine (FLX;
20 mg kg 1 per day, intraperitoneally) or saline. (a) Immunohistochemical images showing NeuroD-positive progenitors in the dentate gyrus (DG) of mice. Box insets
represent regions of high-magnification photomicrographs. Scale bars: lower magnification¼ 100mm and high magnification¼ 20mm. (b) Quantitative analysis indicated a
significant increase in the number of NeuroD-positive cells in serotonin transporter-small interference RNA (SERT-siRNA)-treated mice (four dose) compared with vehicle and
ns-siRNA-treated mice (n¼ 5–9 mice). One-way analysis of variance (ANOVA) showed an effect of group (F2,11¼ 5.87, Po0.05). (c) Representative photomicrographs
showing DCX-positive cells, bearing a complex dendritic morphology in the DG of mice. Scale bar¼ 20mm. (d) Quantitative analysis revealed a significant increase in the
number of DCX-positive cells in both 15-day FLX (F2,29¼ 7.71, Po0.01) and four dose SERT-siRNA-treated mice (F2,18¼ 5.94, Po0.05) (n¼ 6–10). ^ ^Po0.01 versus
saline-treated mice; *Po0.05, **Po0.01 versus vehicle and ns-siRNA-treated mice. Values are mean±s.e.m.
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Figure 5 Serotonin transporter (SERT) silencing enhances hippocampal plasticity-associated gene expression. Mice were infused with four dose SERT- or nonsense siRNA (ns-
siRNA; 10mg per day) or vehicle into dorsal raphe nucleus (DR). Other groups of mice were treated with 4 or 15-day fluoxetine (FLX; 20 mg kg 1 per day, intraperitoneally) or saline.
(a–d) Representative autoradiograms of hippocampal sections of mice are shown for (a) brain-derived neurotrophic factor (BDNF), (b) vascular endothelial growth factor (VEGF), (c)
activity-regulated cytoskeletal protein (Arc) and (d) cAMP response element binding protein (CREB) mRNA expression. Scale bar¼ 100mm. Densitometric analyses were performed
in different hippocampal regions: CA1, CA2, CA3 and dentate gyrus (DG), shown in the cresyl violet-stained section (top). Levels of mRNA for each gene are shown in the bar graphs
next to the representative autoradiograms (n¼ 4–5 mice). (a) BDNF mRNA levels in DG were significantly increased after 15-day FLX treatment compared with saline-treated mice
(two-way analysis of variance (ANOVA): effect of region F3,33¼ 5.76 and interaction group-by-region F6,33¼ 7.86). However, serotonin transporter-small interference RNA (SERT-
siRNA) treatment (four dose) increased BDNF expression in CA1, CA3 and DG compared with respective control groups (significant effect of group F2,8¼ 18.03 and region
F3,24¼ 4.33). (b) VEGF mRNA levels were augmented in all hippocampal subfields after FLX (15-day) or SERT-siRNA (four dose) treatments compared with respective control
groups (two-way ANOVA; FLX: effect of group F2,10¼ 10.11, region F3,30¼ 12.80 and interaction F6,30¼ 4.54; SERT-siRNA: effect of group F2,8¼ 17.32, region F3,24¼ 5.00 and
interaction F6,24¼ 5.42). (c) Arc mRNA levels in DG were significantly increased following FLX (15-day) compared with saline-treated mice (two-way ANOVA: effect of group
F2,11¼ 9.30, region F3,33¼ 4.93 and interaction group-by-region F6,33¼ 7.75). SERT-siRNA treatment (four dose) increased Arc expression in CA1 and DG compared with
respective control groups (significant effect of group F2,13¼ 11.53, region F3,39¼ 6.77 and interaction F6,39¼ 4.05). (d) CREB mRNA levels were unchanged following any treatment.
^^^Po0.001 versus saline-treated mice; *Po0.05, **Po0.01, ***Po0.001 versus vehicle and ns-siRNA-treated mice. Values are mean±s.e.m.
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treatment fully disrupts the 5-HT1A-autoreceptor function
and—unlike fluoxetine—decreases their expression in DR,
thus hastening the adaptive presynaptic mechanisms in
serotonergic neurotransmission.
The fast-acting antidepressant potential of SERT-siRNA
was further confirmed by its ability to increase neurogenesis
and to activate the expression of plasticity gene in the adult
mouse HPC. It is well accepted that antidepressants share the
common property to positively modulate cellular growth and
plasticity in mood-related brain areas. Indeed, plasticity-
associated gene expression and neurogenesis are consid-
ered to be specific markers of antidepressant action.56–59
However, these effects require prolonged (for example, 42
weeks) administration of antidepressants drugs.62–64 One of
the more relevant findings of the present study is the
observation that short-term SERT-siRNA treatment increased
hippocampal progenitor proliferation using two different
markers (5-Bromo-20-deoxyuridine and Ki-67), an effect
produced only after 15-day pharmacological SERT blockade.
This was accompanied by an increase in the number of
NeuroD- and DCX-positive cells, whose morphological com-
plexity suggests that the integration of immature neurons into
hippocampal networks may be accelerated by SERT-siRNA.
In parallel, SERT-siRNA ( four dose)—but not fluoxetine—,
also enhanced the expression of trophic factors such as
BDNF and VEGF, as well as that of the activity-dependent Arc
gene in several HPC subfields. Neuronal activity recruits
latent stem/progenitor cells in the adult HPC, increasing the
expression of trophic factors.65 Therefore, these could serve
to link neuronal activity to structural plasticity in the
hippocampal neurogenic niche. Future experiments will
examine whether this neurogenic effect is required for the
antidepressant-like responses elicited by SERT-siRNA
treatment.
In conclusion, our results show that siRNA-induced
selective SERT knockdown evokes a number of behavioral,
neurochemical and cellular responses predictive of clinical
antidepressant activity. Notably, these effects occur after
short-term SERT-siRNA treatment and are remarkably faster
and—in most instances—more effective than those elicited by
persistent SERT blockade with the SSRI fluoxetine. Together
with previous observations,18,35,40 the present data support
the usefulness of RNAi strategies, stimulating serotonergic
transmission as a new therapeutic class overcoming the two
main limitations of current pharmacological treatments, that
is, limited efficacy and slowness of action.
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